Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

Nitrous

Nitrous molecule structureNitrous molecule structure
Psychoactive Class
Chemical Class

Nitrous oxide is an atypical dissociative inhalant with the chemical formula N₂O. First identified by Joseph Priestly in 1772, its anesthetic properties were later discovered in the 19th century, earning it the name 'laughing gas' due to its euphoria and laughter-inducing effects. When inhaled, it produces rapid analgesia, mild sedation, and brief psychedelic dissociation.1 Widely used medically in surgery and dentistry, it is also commonly encountered recreationally through whipped cream chargers.1 Chronic abuse may cause neurological damage through vitamin B12 inactivation.1

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~4 g
Light4-8 g
Moderate8-16 g
Strong16-40 g
Heavy40+ g

Doses are commonly measured in whipped cream chargers; a single standard cartridge contains about 8 g of nitrous oxide and provides roughly one to three lungfuls of gas. One or two lungfuls is generally sufficient for a short experience, and a typical session involves 1-5 cartridges or balloons. Repeated use in quick succession should be avoided. Inhalation of pure nitrous oxide causes oxygen deprivation, which can lead to low blood pressure, fainting, and cardiac events, particularly with continuous inhalation from a mask or gas canister or with prolonged breath-holding. Non-medical formulations such as whipped-cream chargers contain no oxygen. Nitrous oxide is neurotoxic and can cause irreversible neurological damage; heavy single-session use (at or above 400 g, roughly 200 L of gas) or regular daily or weekly use has been associated with peripheral neuropathy including ataxia and paresthesia. Loss of gross and fine motor control, balance, and coordination is prominent, so users should be seated before onset to avoid falls and injury.

Duration

Onset5-10 seconds
Come Up5-10 seconds
Peak15-30 seconds
Offset1-5 minutes
After Effects15-30 minutes
Total1-5 minutes

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

Cognitive

Visual

Hallucinatory States

In comparison to other more classical dissociatives, hallucinations are particularly rare with nitrous but possible at high dosages.

Internal hallucinations

Suppressions

Auditory

The auditory effects found with nitrous oxide, although simplistic, are famously known to be particularly intense and consistent in their manifestation when compared to other hallucinogens.

Forked from Subjective Effect Documentation byJosie Kins February 2014.

See also: Dissociative Intensity Scale, Subjective Effects of Dissociatives

Pharmacology

Pharmacodynamics

The mechanism of action of nitrous oxide is not fully understood, but it directly modulates a broad range of ligand-gated ion channels.2 NMDA receptor antagonism appears to be its primary pharmacological action, with an approximate EC50 of 30-40% inhaled concentration in cultured hippocampal neurons; even at 80%, N2O acts only as a partial inhibitor.citation needed It moderately blocks β2-subunit-containing nicotinic acetylcholine receptors (with preference for α4β2 over α4β4), weakly inhibits AMPA, kainate, GABAC, and 5-HT3 receptors, and slightly potentiates GABAA and glycine receptors. It activates two-pore-domain potassium channels, particularly TREK-13, and weakly inhibits Cav3.2 low-voltage-activated calcium channels.citation needed The analgesic properties of N2O appear to involve the release of endogenous opioid peptides in the brainstem, which disinhibits descending noradrenergic neurons that modulate pain signaling at α2-adrenoceptors in the spinal cord, and N2O has been reported to bind directly at opioid receptor sites. N2O may also influence nitric oxide signaling in the central nervous system.

Pharmacokinetics

Nitrous oxide has very low solubility in blood, with a blood/gas partition coefficient of 0.46, which provides rapid onset and equally rapid clearance once administration ceases.6 Predicted ADMET modeling indicates that N2O is not a substrate of major cytochrome P450 enzymes (CYP2C9, CYP2D6, CYP3A4) and has low CYP inhibitory promiscuity.

Metabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Tolerance to many of the effects develops with prolonged and repeated use, resulting in users needing to administer increasingly large doses to achieve the same effects.
Baseline Reset
1-2 weeks
Half Tolerance
3-7 days

Harm Potential

Addiction & Dependence

Psychological

Moderate

Nitrous oxide has gained the nickname 'hippy-crack' due to its tendency toward compulsive redosing in some users. While uncommon, individuals with easy access to large quantities may use it many times daily.citation needed The substance is considered to have low to moderate abuse potential overall.

Physical

Low

Physical dependence with psychological symptoms is possible with continuous use. The substance does not produce a classical physical withdrawal syndromecitation needed, though psychological dependence can develop in heavy users.

Toxicity

Central Nervous System

Heavy and frequent long-term use can cause serious neurological damage including subacute combined degeneration of the spinal cordcitation needed; occasional recreational use at typical doses carries minimal risk, while chronic daily or weekly use significantly increases the likelihood of peripheral neuropathy.

Hematological

Chronic heavy use can cause megaloblastic changescitation needed and, in severe cases, agranulocytosis; these effects are associated with prolonged B12 inactivation rather than occasional use.

Cardiovascular

Hypoxia from improper use can cause low blood pressure, fainting, and cardiac arrhythmia; serious cardiac events are rare and typically associated with pre-existing conditions or continuous inhalation without oxygen.

Respiratory

High-pressure administration directly from tanks can rupture blood vessels in the lungs and cause pneumothorax; this risk is eliminated by releasing gas into a balloon first.

Oropharyngeal

Direct inhalation from tanks or whippits can cause frostbite to the lips, throat, larynxcitation needed, and bronchi due to extremely cold gas temperatures.

Psychosis Risk

Psychological issues including personality changes, mood disorders, psychosis, and hallucinations can occurcitation needed, primarily in the context of chronic heavy use and associated B12 deficiency rather than acute intoxication.

Seizure Risk

A short period of slight hypoxia from nitrous oxide use could potentially raise the chance of seizure in some users. Persons suffering from epilepsy are advised not to consume nitrous oxide.

History & Culture

Discovery and Early Research

Nitrous oxide was first synthesized in 1772 by English natural philosopher and chemist Joseph Priestley, who initially called it "dephlogisticated nitrous air."citation needed He produced the gas by heating iron filings dampened with nitric acid and passing the resulting vapor through water to

Legality

International

World Health Organization's List of Essential Medicines

By Country

Illegal6
Japan flagJapanIllegal
Netherlands flagNetherlandsIllegal
New Zealand flagNew ZealandIllegal
Portugal flagPortugalIllegal
South Korea flagSouth KoreaIllegal
United Kingdom flagUnited KingdomIllegal
Controlled / restricted8
Brazil flagBrazilRestricted
Czech Republic flagCzech RepublicRestricted
Denmark flagDenmarkRestricted
France flagFranceRestricted
Germany flagGermanyRestricted
India flagIndiaRestricted
Norway flagNorwayRestricted
Russia flagRussiaRestricted
Prescription2
Austria flagAustriaPrescription only
Switzerland flagSwitzerlandPrescription only
Legal / decriminalized7
United States flagUnited StatesLegal (regulated)
Australia flagAustraliaLegal (regulated)
Canada flagCanadaLegal (regulated)
Colombia flagColombiaLegal (regulated)
Indonesia flagIndonesiaLegal (regulated)
Mexico flagMexicoLegal (regulated)
Sweden flagSwedenLegal (regulated)
Not scheduled2
Poland flagPolandNot scheduled
Singapore flagSingaporeNot scheduled

References

Citations

  1. World Health Organization. (2023). Nitrous oxide: Critical Review Report. 46th Expert Committee on Drug Dependence, 1-40. https://cdn.who.int/media/docs/default-source/46th-ecdd/nitrous-oxide_46th-ecdd_critical-review_public-version.pdf123
  2. Tomohiro Yamakura, & R. Adron Harris. (2000). Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology, 93(4), 1095–1101. https://doi.org/10.1097/00000542-200010000-000341234
  3. Marco Gruss, Trevor J. Bushell, Damian P. Bright, William R. Lieb, Alistair Mathie, & Nicholas P. Franks. (2004). Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Molecular Pharmacology, 65(2), 443–452. https://doi.org/10.1124/mol.65.2.44312
  4. Michael C. Kalmoe, Amanda M. Janski, Charles F. Zorumski, Peter Nagele, Ben Julian A. Palanca, & Charles R. Conway. (2020). Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents. Journal of the Neurological Sciences, 412, Article 116778. https://doi.org/10.1016/j.jns.2020.116778123456
  5. P. Orestes, D. Bojadzic, J. Lee, E. Leach, R. Salajegheh, M. R. Digruccio, M. T. Nelson, & S. M. Todorovic. (2011). Free radical signalling underlies inhibition of CaV3.2 T-type calcium channels by nitrous oxide in the pain pathway. The Journal of Physiology, 589(1), 135–148. https://doi.org/10.1113/jphysiol.2010.1962201
  6. Daniel E. Becker, & Morton Rosenberg. (2008). Nitrous Oxide and the Inhalation Anesthetics. Anesthesia Progress, 55(4), 124–131. https://doi.org/10.2344/0003-3006-55.4.1241
  7. Cyrille De Halleux, & David N. Juurlink. (2023). Diagnosis and management of toxicity associated with the recreational use of nitrous oxide. CMAJ, 195(32), E1075–E1081. https://doi.org/10.1503/cmaj.2301961
  8. Nosaiba K Ezzelarab, & Tarek Matar. (2025). Recreational Nitrous Oxide Misuse: Anaesthetic Challenges and Perioperative Complications Including Airway Burns and Neurological Sequelae. Cureus, 17(8), Article e89232. https://doi.org/10.7759/cureus.892321
  9. Abderrahim Oussalah, Mélissa Julien, Julien Levy, & Jean-Louis Guéant. (2019). Global Burden Related to Nitrous Oxide Exposure in Medical and Recreational Settings: A Systematic Review and Individual Patient Data Meta-Analysis. Journal of Clinical Medicine, 8(4), Article 551. https://doi.org/10.3390/jcm804055112
  10. Home Office. (2014). Drug Misuse: Findings from the 2013 to 2014 Crime Survey for England and Wales. UK Home Office. https://www.gov.uk/government/statistics/drug-misuse-findings-from-the-2013-to-2014-csew/drug-misuse-findings-from-the-201314-crime-survey-for-england-and-wales1

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Lyrea avatar
    Step 2 · First-pass review

    A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Nitrous article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.